Connor Clark & Lunn Investment Management Ltd. opened a new position in Kura Oncology, Inc. during the second quarter. The firm purchased 996,114 shares. This investment is valued at approximately $10,927,000. The purchase represents a 1.12% ownership stake in the company.
CEO Troy Wilson also purchased 100,000 shares on August 24. His transaction was valued at approximately $1.24 million.
Kura’s drug, KOMZIFTI (ziftomenib), generated $9.1 million in net product revenue during its first two quarters. The treatment currently shows significant sequential commercial growth.